Gynecologic Cancer News

The Metropolitan Chicago Breast Cancer Task Force held an evening art gallery event for its survivors in October. For the task force, it was a celebration of successful efforts in navigating underserved, minority patients with cancer toward quality care.

The trends are clear — not only do ethnic and racial minority groups face poorer cancer outcomes, they also are less frequently invited to participate in clinical trials, more often experience delays in treatment and initiation of palliative care, and are less likely to be offered genetic testing.

Novel 3-D transvaginal ultrasound technology appeared safe and effective in improving delivery of brachytherapy among a small cohort of women with gynecologic cancer, according to study results.

An investigational blood-based assay identified new potential biomarkers for ovarian cancer and, with a multiprotein classifier, may be able to detect early stages of the disease, according to study results.

Comprehensive molecular profiling feasibly identified potentially actionable mutations among children and adolescents with hard-to-treat cancers, according to results of a prospective study published in JAMA Network Open.

Pembrolizumab monotherapy appeared safe and induced durable antitumor responses in patients with advanced cervical cancer, according to interim results of the phase 2 KEYNOTE-158 study published in Journal of Clinical Oncology.

The University of Illinois Cancer Center has received a 3-year, $1.5 million grant from the Bristol-Myers Squibb Foundation to support programs intended to reduce cancer disparities in the Chicago area, according to a press release.

An investigational therapeutic vaccine eliminated high-grade cervical intraepithelial neoplasia and underlying HPV infection among one-third of women in a phase 2 trial, according to study results.

DESTIN, Fla. — Patients with gout are 50% more likely to develop cancer, with prostate cancer being the most common among that population, according to a presenter at the North American Young Rheumatology Investigator Forum.

Breast, colorectal and ovarian cancers are among the most common cancers that affect women, according to the American Cancer Society. The mortality rates associated with these cancers in women vary drastically. This year, there will be an estimated 41,760 deaths attributed to breast cancer, 23,240 deaths attributed to colorectal cancer, and 13,980 deaths attributed to ovarian cancer in the United States.